You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Rasagiline Mesylate

Showing 1 - 25 of 552
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Parkinson's Disease Trial in United States (Rasagiline, Placebo)

Completed
Has Results
  • Parkinson's Disease
  • Birmingham, Alabama
  • +39 more
Nov 6, 2021

REM Sleep Behavior Disorder, Parkinson Disease, Synucleinopathies Trial (Rasagiline)

Not yet recruiting
  • REM Sleep Behavior Disorder
  • +2 more
  • (no location specified)
Nov 6, 2022

Multiple Myeloma Trial in Houston (Belumosudil mesylate)

Not yet recruiting
  • Multiple Myeloma
  • Belumosudil mesylate
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2023

Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in Canada, United States (Dasatinib, Imatinib Mesylate, Laboratory

Active, not recruiting
Has Results
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Burbank, California
  • +340 more
Jan 28, 2023

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease Trial in United States (drug, other,

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Minimal Residual Disease
  • Goodyear, Arizona
  • +237 more
Jan 3, 2023

Gastrointestinal Stromal Tumor of Rectum Trial in Fuzhou (Imatinib Mesylate, Local resection)

Not yet recruiting
  • Gastrointestinal Stromal Tumor of Rectum
  • Imatinib Mesylate
  • Local resection
  • Fuzhou, Fujian, China
    Weizhong Jiang
Jul 23, 2023

Hyperpigmentation, Post-inflammatory Hyperpigmentation, Acne Trial (Topical Cetyl Tranexamate Mesylate)

Not yet recruiting
  • Hyperpigmentation
  • +2 more
  • Topical Cetyl Tranexamate Mesylate
  • (no location specified)
Oct 6, 2023

Immunotherapy, Gastrict Cancer Trial in Fuzhou (Tislelizumab, Apatinib Mesylate, oxaliplatin)

Recruiting
  • Immunotherapy
  • Gastrict Cancer
  • Fuzhou, China
    Fujian cancer hospital
Jan 17, 2023

Immunotherapy Gastrict Cancer Trial (Tislelizumab, apatinib, oxaliplatin)

Not yet recruiting
  • Immunotherapy Gastrict Cancer
  • (no location specified)
Jan 17, 2023

Breast Cancer Trial in United States (gemcitabine HCl, imatinib mesylate)

Terminated
Has Results
  • Breast Cancer
  • gemcitabine hydrochloride
  • imatinib mesylate
  • Chicago, Illinois
  • +8 more
Aug 12, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

Terminated
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Bintrafusp Alfa
  • Eribulin Mesylate
  • Houston, Texas
  • +1 more
Oct 27, 2022

HIV Trial in San Diego (Cenicriviroc Mesylate (CVC), Placebo)

Withdrawn
  • HIV Infections
  • Cenicriviroc Mesylate (CVC)
  • Placebo
  • (no location specified)
Dec 19, 2022

Cholangiocarcinoma Trial (Carrilizumab, Albumin-bound paclitaxel, Apatinib)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Dec 9, 2022

Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Imatinib Mesylate
  • Ipilimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 1, 2022

NSCLC Trial in Shanghai (BL-B01D1, Osimertinib Mesylate Tablets)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
May 25, 2023

Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,

Recruiting
  • Esophageal Cancer by AJCC V8 Stage
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 12, 2023

SARS-CoV Infection, COVID-19 Trial (Mitoquinone/mitoquinol mesylate, Placebo)

Not yet recruiting
  • SARS-CoV Infection
  • COVID-19
  • Mitoquinone/mitoquinol mesylate
  • Placebo
  • (no location specified)
Jun 1, 2023

Camrelizumab Combined With Apatinib Mesylate in Unresectable

Recruiting
  • Hepatocellular Carcinoma
    • Fuzhou, Fujian, China
      Mengchao Hepatobiliary Hospital, Fujian Medical University
    Aug 24, 2022

    Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE

    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Nanjing, Jiangsu, China
      Jiangsu Province Hospital
    Nov 6, 2022

    Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral

    Recruiting
    • Locally Advanced Renal Pelvis Urothelial Carcinoma
    • +20 more
    • Duarte, California
    • +16 more
    Aug 10, 2022

    Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

    Active, not recruiting
    • Metastatic Castration Resistant Prostate Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Sep 23, 2022

    Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

    Recruiting
    • Diffuse Large B Cell Lymphoma，DLBCL
    • PM 8.4 mg/m2
    • PM 11.2 mg/m2
    • Chengdu, Sichuan, China
      West China Hospital Sichuan University
    Jan 15, 2023

    Healthy Volunteers Trial in Changsha (TY-9591 Tablets under Fasted Condition - Arm1, Osimertinib Mesylate Tablets under Fasted

    Completed
    • Healthy Volunteers
    • TY-9591 Tablets under Fasted Condition - Arm1
    • +5 more
    • Changsha, Hunan, China
      Hunan Provincial Tumor Hospital
    Dec 6, 2022

    Critical Illness, Anticoagulation Trial (Nafamostat Mesylate, Unfractionated Heparin)

    Not yet recruiting
    • Critical Illness
    • Anticoagulation
    • Nafamostat Mesylate
    • Unfractionated Heparin
    • (no location specified)
    Sep 23, 2022

    HIV-1-infection Trial in United States (CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg)

    Not yet recruiting
    • HIV-1-infection
    • CVC 150 mg
    • +3 more
    • Los Angeles, California
    • +16 more
    Nov 22, 2022